generic medications are

Derisking Process

Once selected, technologies enter a three-stage process that identifies and addresses and reduces key risks associated with commercializing early technology.

Phase One consists of early-stage intellectual property assessment, technology validation, and an interview of the principal investigator or inventor. Nidus seeks to retain the principal investigator as a consultant and the option to license any technology with sufficient potential to advance to Phase Two.

Phase Two entails construction of a detailed intellectual property strategy, including freedom-to-operate strategy, a regulatory assessment with corporate partners, and in-depth analysis of the commercial opportunity, including engaging technical and business experts to identify barriers to commercialization and best market opportunities.

Phase Three involves a make-or-break experiment, prototype fabrication, or other tangible evaluation of the technology. At the end of this process the technology is well positioned to emerge investment-ready, as a start-up or license opportunity.